Sensus Healthcare is a medical device maker best known for its superficial radiation therapy (SRT) systems—the SRT-100/Vision—used to treat non-melanoma skin cancers and keloids. The $5.00 figure used here is not an official consensus but a calculated average of three current, verifiable analyst price targets: Alliance Global Partners at $5.50 (maintained August 17, 2026), Maxim Group at $6.00 (maintained August 15, 2026), and Lake Street at $4.00 (lowered from $4.50 on August 14, 2026). Their arithmetic mean is about $5.17, rounded to $5.00, with a range of $4.00 to $6.00.
All three firms rate the stock a Buy, but the wide $4.00-to-$6.00 spread signals real disagreement about how quickly a recovery takes hold. Maxim's Anthony Vendetti is the most optimistic, arguing the company is nearing an operational inflection point on strengthening demand and new reimbursement codes. Lake Street's Ben Haynor took a more cautious view after the second quarter, cutting his target. Notably, the average target has fallen sharply—from around $8.00 a year ago to roughly $5.17 today—reflecting repeated downward revisions rather than a stable, rising trajectory.
With the stock near $2.75 and a 52-week range of roughly $2.66 to $5.49, the $5.00 target implies about an 80% upside, a very large move that would effectively return the shares to their prior peak zone. The path would require a decisive turnaround in revenue recognition. In the second quarter of 2026, revenue fell to about $2.3 million from $7.3 million a year earlier, largely because eight SRT systems—each roughly $250,000—were delayed by third-party financing issues. Management has since severed ties with the bank involved and expects those sales to be recognized in the third quarter, a key near-term catalyst that analysts believe could re-accelerate the top line.
The most compelling support is reimbursement. New dedicated CPT (Current Procedural Terminology) codes took effect in 2026, and early CMS (Centers for Medicare & Medicaid Services) reimbursement under those codes could improve physician economics and drive broader adoption of the SRT platform. Maxim also points to emerging international opportunities in markets such as Australia and New Zealand. If the delayed systems are recognized as guided and demand from new customers materializes, revenue growth forecasts—estimated at a roughly 20% annual pace by some aggregators—could begin to close the gap between the current price and analyst targets.
The obstacles are substantial. The company swung to a wider GAAP (generally accepted accounting principles) net loss in the second quarter, including a valuation allowance, and remains unprofitable on a trailing basis. Sales are heavily dependent on a limited number of large customers—the absence of its largest customer's orders has previously driven dramatic shortfalls—and financing delays have repeatedly pushed revenue recognition out. Thin analyst coverage also means the "consensus" rests on just three voices, and the steady downward revision of targets over the past year shows that prior recovery assumptions have not been met.
The shares sit near the bottom of their 52-week range, with the prior high around $5.49 acting as the nearest major resistance zone—coincidentally just above the $5.00 target. The $2.66 area represents a key support level. In September 2026, the stock slipped below its 50-day moving average, reflecting waning short-term momentum, and any sustained advance would first need to reclaim intermediate moving averages before approaching the $5.00 level.
Analyst price targets typically reflect a research horizon of about 12 months, though no firm horizon is explicitly stated in these reports. Investors should watch the third-quarter earnings release for evidence that the eight delayed systems were recognized, any updates on adoption of the new 2026 CPT codes and CMS reimbursement, gross-margin and cash trends, and whether analysts raise or cut their targets after results. Additional coverage initiations or downgrades would also matter given how thin the current consensus is.
Beyond fundamental analysis, traders increasingly turn to automated tools for a real-time view of momentum. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals can help traders discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how the platform's signal engine is currently reading the market.
Can Sensus Healthcare reach $5.00? The target—an average of three current analyst targets ranging from $4.00 to $6.00—is mathematically plausible but demanding, requiring roughly an 80% advance from near $2.75. The bull case rests on new reimbursement codes and a third-quarter revenue recovery from delayed system sales, while the bear case points to steep losses, financing disruption, and customer concentration. Analysts agree the stock is a Buy but disagree sharply on magnitude, and their targets have been falling, not rising. The next earnings report and any revision to those targets will be the clearest test of whether the $5.00 objective remains realistic.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SRTS has been loosely correlated with LUNG. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SRTS jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To SRTS | 1D Price Change % | ||
|---|---|---|---|---|
| SRTS | 100% | +3.77% | ||
| LUNG - SRTS | 57% Loosely correlated | N/A | ||
| HAE - SRTS | 45% Loosely correlated | +3.51% | ||
| AORT - SRTS | 34% Loosely correlated | -0.82% | ||
| GMED - SRTS | 32% Poorly correlated | -1.49% | ||
| MTD - SRTS | 28% Poorly correlated | -0.62% | ||
More | ||||
| Ticker / NAME | Correlation To SRTS | 1D Price Change % |
|---|---|---|
| SRTS | 100% | +3.77% |
| Health Services category (239 stocks) | -3% Poorly correlated | +0.37% |
| Medical/Nursing Services category (138 stocks) | -3% Poorly correlated | +0.85% |